PI3K inhibitor promotes tumor vessel normalization and improves treatment outcomes of breast cancer with doxorubicin

HS-173 is a specific inhibitor of the Phosphoinositide 3-Kinase α (PI3Kα) subtype. Although it was shown to potentially inhibit tumor angiogenesis, experimental validation studies are still needed. This study provides an experimental basis for the role of HS-173 in breast cancer. A mouse model of subcutaneous transplantation breast cancer was constructed. The mice were treated with different concentrations of HS-173. Immunohistochemical staining was used to detect tumor microvessel density, and the appropriate concentration was determined. Immunofluorescence was used to detect the morphology integrity of tumor vessels’ lumen, transmission electron microscopy to detect tight junctions between endothelial cells and the integrity of the basement membrane, Doppler ultrasound to detect tumor blood perfusion, and small animal live imaging to detect the penetration of doxorubicin in the tumor tissues. After HS-173 treatment, the number of tumor interstitial microvessels decreased, the lack of tumor vascular lumen was reduced, and the continuity and integrity of the vascular lumen were increased. Vascular endothelial cells showed complete morphology with good tight junctions. The extracellular matrix was rich in components and tended to form basement membranes. HS-173 also increased the blood perfusion in the tumor tissue compared with the doxorubicin treatment alone. Further, the fluorescence signal intensity of the tumor tissue doxorubicin was significantly enhanced after HS-173 treatment. The PI3K inhibitor HS-173 showed promising potential in inhibiting tumor angiogenesis and improving the structure and function of blood vessels in the tumor microenvironment.

Tumor blood vessels; Normalization of tumor blood vessels; PI3K inhibitors; Breast cancer

[1] Parmar D, Apte M. Angiopoietin inhibitors: a review on targeting tumor angiogenesis. European Journal of Pharmacology. 2021; 899: 174021.

[2] Haibe Yolla, Kreidieh Malek, El Hajj Hiba, Khalifeh I, Mukherji D, Temraz S, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Frontiers in Oncology. 2020; 10: 221.

[3] Carmen García-Pravia, José A Galván, Natalia Gutiérrez-Corral, Solar-García L, García-Pérez E, García-Ocaña M, et al. Overexpression of COL11A1 by cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic cancer. PLoS One. 2013; 8: e78327.

[4] Lai Victoria, Neshat Sarah Y, Rakoski Amanda, Pitingolo J, Doloff JC. Drug delivery strategies in maximizing anti-angiogenesis and antitumor immunity. Advanced Drug Delivery Reviews. 2021; 179: 113920.

[5] Kaymak I, Williams KS, Cantor JR, Jones RG. Immunometabolic interplay in the tumor microenvironment. Cancer Cell. 2021; 39: 28–37.

[6] Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Letters. 2015; 368: 7–13.

[7] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[8] Kim SJ, Jung KH, Son MK, Park JH, Yan HH, Fang Z, et al. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery. Cancer Letters. 2017; 403: 339–353.

[9] Zheng R, Li F, Li F, Gong A. Targeting tumor vascularization: promising strategies for vascular normalization. Journal of Cancer Research and Clinical Oncology. 2021; 147: 2489–2505.

[10] Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017; 20: 409–426.

[11] Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiological Reviews. 2011; 91: 1071–1121.

[12] Feng Y, Deng L, Guo H, Zhao Y, Peng F, Wang G, et al. The anti-colon cancer effects of essential oil of curcuma phaeocaulis through tumour vessel normalisation. Frontiers in Oncology. 2021; 11: 728464.

[13] Erskine L, François U, Denti L, Joyce A, Tillo M, Bruce F, et al. VEGF-A and neuropilin 1 (NRP1) shape axon projections in the developing CNS via dual roles in neurons and blood vessels. Development. 2017; 144: 2504–2516.

[14] Jia JD, Jiang WG, Luo X, Li RR, Zhao YC, Tian G, et al. Vascular endothelial growth factor B inhibits insulin secretion in MIN6 cells and reduces Ca2+ and cyclic adenosine monophosphate levels through PI3K/AKT pathway. World Journal of Diabetes. 2021; 12: 480–498.

[15] Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proceedings of the National Academy of Sciences. 2015; 112: 14325–14330.

[16] Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, et al. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Scientific Reports. 2021; 11: 3388.

[17] Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, et al. High-circulating Tie2 is Associated with pathologic complete response to chemotherapy and antiangiogenic therapy in breast cancer. American Journal of Clinical Oncology. 2016; 39: 248–254.

[18] Harry JA, Ormiston ML. Novel pathways for targeting tumor angiogene-sis in metastatic breast cancer. Frontiers in Oncology. 2021; 11: 772305.

[19] Zhu D, Li Y, Zhang Z, Xue Z, Hua Z, Luo X, et al. Recent advances of nanotechnology-based tumor vessel-targeting strategies. Journal of Nanobiotechnology. 2021; 19: 435.

[20] Hultgren NW, Fang JS, Ziegler ME, Ramirez RN, Phan DTT, Hatch MMS, et al. Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis. Nature Communications. 2020; 11: 5400.

[21] Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. Journal of Experimental & Clinical Cancer Research. 2019; 38: 173.

[22] Shah AA, Kamal MA, Akhtar S. Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. Current Drug Metabolism. 2021; 22: 50–59.

[23] Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF–VEGFR2 signalling. Nature. 2012; 484: 110–114.